Beleodaq
Payments companies reported to CMS as associated with Beleodaq. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Beleodaq, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Beleodaq
These are the largest totals companies reported as associated with Beleodaq. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Owen Oconnor | New York, NY | Medical Oncology | $130,170.51 |
| Francine Foss | New Haven, CT | Medical Oncology | $40,976.27 |
| Hayder Saeed | Tampa, FL | Hematology & Oncology | $28,413.90 |
| Yumeng Zhang | Tampa, FL | Hematology & Oncology | $27,203.73 |
| John Reneau | Columbus, OH | Hematology (Internal Medicine) | $19,356.77 |
| Christina Poh | Duarte, CA | Hematology (Internal Medicine) | $17,301.85 |
| Matthew Lunning | Omaha, NE | Medical Oncology | $15,836.51 |
| Sanjay Kaul | Los Angeles, CA | $14,400.00 | |
| Swaminathan Iyer | Houston, TX | Hematology (Internal Medicine) | $13,724.28 |
| Salvia Jain | Boston, MA | Hematology (Internal Medicine) | $12,197.15 |
Prescribed Beleodaq?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.